Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ELTX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 05, 2026
Report Source: 2026 1st Quarter Report
Elicio Therapeutics Inc. Stock Analysis ELTX
United States Health Care Micro Cap Report: Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Read More Elicio Therapeutics Inc (ELTX) Chart
Key Statistics of Elicio Therapeutics Inc (ELTX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$4.09Volume
1.57MP/E Ratio (TTM)
-52 Week Range
Market Cap
188.95MAvg. Volume
3.83MDividend Yield
-Financial Metrics & Statements of Elicio Therapeutics Inc (ELTX)
FAQ's for Elicio Therapeutics Inc (ELTX)
- According to Musaffa’s Shariah screening methodology, Elicio Therapeutics Inc (ELTX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Elicio Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Elicio Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Elicio Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Elicio Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Elicio Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.